Company profile
Kelonia Therapeutics, Inc.
Privately held: no public share price (Kelonia Therapeutics is a privately held clinical-stage in vivo CAR-T company (KLN-1010, anti-BCMA for multiple myeloma), $60M raised in private capital to date. Eli Lilly announced a definitive agreement (announced 2026-04-20) to acquire Kelonia for up to $7B, expected to close in H2 2026 (investor.lilly.com, cnbc.com); not yet closed as of this review, so still a standalone private company. Sources: https://clinicaltrials.gov/study/NCT07075185 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCMAGene therapy / editing | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.